Pasithea Therapeutics Cor...
(KTTA)
undefined
undefined%
At close: undefined
2.65
-0.93%
After-hours Dec 13, 2024, 03:59 PM EST
Company Description
Pasithea Therapeutics Corp., a biotechnology company, engages in research and discovery of treatments for psychiatric and neurological disorders.
It also intends to operate anti-depression clinics and provide business support services using trained pharmacists to administer intravenous infusions of ketamine.
The company was incorporated in 2020 and is headquartered in Miami Beach, Florida.
Pasithea Therapeutics Corp.
| Country | United States |
| IPO Date | Sep 15, 2021 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 8 |
| CEO | Dr. Tiago Reis Marques M.D., Ph.D. |
Contact Details
Address: 1111 Lincoln Road Miami Beach, Florida United States | |
| Website | https://www.pasithea.com |
Stock Details
| Ticker Symbol | KTTA |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| CIK Code | 0001841330 |
| CUSIP Number | 70261F103 |
| ISIN Number | US70261F2020 |
| Employer ID | 85-1591963 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Tiago Reis Marques M.D., Ph.D. | Chief Executive Officer & Director |
| Daniel H. Schneiderman | Chief Financial Officer |
| Dr. Yassine Bendiabdallah Ph.D. | Chief Operating Officer & Head of UK Clinics |
| Dr. Graeme Currie Ph.D. | Chief Development Officer |
| Dr. Lawrence Steinman BA, M.D., Ph.D. | Co-Founder, MD & Executive Chairman |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Nov 26, 2024 | 424B5 | Filing |
| Nov 26, 2024 | 8-K | Current Report |
| Nov 14, 2024 | SC 13G | Statement of acquisition of beneficial ownership b... |
| Nov 13, 2024 | 10-Q | Quarterly Report |
| Oct 11, 2024 | 424B3 | Filing |
| Oct 07, 2024 | S-3 | Filing |
| Sep 30, 2024 | 8-K | Current Report |
| Sep 26, 2024 | 8-K | Current Report |
| Aug 13, 2024 | 10-Q | Quarterly Report |
| Jun 26, 2024 | 8-K | Current Report |